stoxline Quote Chart Rank Option Currency Glossary
  
X4 Pharmaceuticals, Inc. (XFOR)
0.4807  0.012 (2.56%)    02-12 16:00
Open: 0.46
High: 0.4903
Volume: 1,392,311
  
Pre. Close: 0.4687
Low: 0.455
Market Cap: 82(M)
Technical analysis
2025-02-12 4:49:11 PM
Short term     
Mid term     
Targets 6-month :  0.77 1-year :  0.95
Resists First :  0.66 Second :  0.81
Pivot price 0.56
Supports First :  0.42 Second :  0.35
MAs MA(5) :  0.5 MA(20) :  0.54
MA(100) :  0.55 MA(250) :  0.77
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  14.6 D(3) :  19
RSI RSI(14): 42.7
52-week High :  1.6 Low :  0.26
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ XFOR ] has closed above bottom band by 25.7%. Bollinger Bands are 10.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.49 - 0.49 0.49 - 0.5
Low: 0.45 - 0.45 0.45 - 0.45
Close: 0.48 - 0.48 0.48 - 0.49
Company Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Headline News

Thu, 13 Feb 2025
HC Wainwright Has Negative Forecast for XFOR FY2028 Earnings - MarketBeat

Wed, 12 Feb 2025
X4 Pharmaceuticals' (XFOR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Thu, 06 Feb 2025
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - Marketscreener.com

Thu, 06 Feb 2025
X4 Pharma's Major Restructuring: 43 Jobs Cut as Company Pivots to Core Drug Development - StockTitan

Mon, 03 Feb 2025
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mon, 03 Feb 2025
X4 Pharma's Latest Employee Stock Plan: Strategic Move to Attract Top Talent - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -72 (M)
Shares Float 0 (M)
Held by Insiders 1.7055e+008 (%)
Held by Institutions 1.2783e+008 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 295000
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.08
Profit Margin 3 %
Operating Margin 131.7 %
Return on Assets (ttm) -6 %
Return on Equity (ttm) 20.7 %
Qtrly Rev. Growth 21.7 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.69
Qtrly Earnings Growth -1.2318e+008 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -6.01
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 1.142e+007
Forward Dividend 1.356e+007
Dividend Yield 2375700000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android